Strengthened profitability and cash flow despite a quarter with macro headwinds. In the third quarter, organic sales decreased by 4.8% in constant currency, but the year-to-date growth remains positive. The work on operational efficiency is having an effect and EBITA increased by SEK 1.0 million while the EBITA margin amounted to 15.5% (13.7%). Cash flow … Read more
In the second quarter of 2025, organic sales adjusted for currency effects increased, driven by steady demand for laboratory equipment and rental of equipment for clinical studies. Operating cash flow improved in the quarter, and EBITA was in line with last year with a stronger margin. Through the new capital structure, ADDvise’s annual interest expenses … Read more
ADDvise Group AB (publ) (“ADDvise” or the “Company”) has mandated Nordea Bank Abp to arrange a series of credit investor meetings commencing on 14 May 2025, to explore the possibility of issuing senior unsecured floating rate bonds with an expected volume of SEK 800 million within a framework of SEK 1,600 million and with a … Read more
In the first quarter of 2025, net revenue increased organically with continued good profitability, which shows stable demand in medical technology and laboratory solutions. Cash flow from operating activities was strong, driven by improved working capital while EBITA, the company’s new main profit measure, decreased compared to the same quarter last year. Through increased operational … Read more
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES), AUSTRALIA, CANADA, BELARUS, HONG KONG, JAPAN, NEW ZEALAND AND RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, … Read more
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES), AUSTRALIA, CANADA, BELARUS, HONG KONG, JAPAN, NEW ZEALAND AND RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, … Read more
The Board of Directors of ADDvise Group AB (“ADDvise” and the “Company”) presents preliminary financial information for the fourth quarter of 2024 and has, in connection therewith, decided to update the Company’s long-term financial targets. Furthermore, the Board of Directors has decided to postpone the planned listing transfer to Nasdaq Stockholm’s main market. The work … Read more
ADDvise Group’s subsidiary MRC Systems has received an order from Rafarm, a leading pharmaceutical company based in Greece. The order is worth approximately EUR 2.6 million. The order involves design, paneling, and installation of a cleanroom and associated accessories. Delivery of the order is scheduled to be completed during Q4 2025. For further information, please … Read more
ADDvise Group’s subsidiary Hettich Labinstrument AB has received an allocation decision from Region Stockholm worth approximately SEK 72 million. The allocation decision involves the delivery of blood specimen collection equipment over a four-year period, commencing in May 2025. The allocation decision can be appealed up until December 20, 2024. For further information, please contact: Staffan … Read more
ADDvise is exploring the possibility of divesting its subsidiary AB Germa. Germa has shifted its focus primarily towards defense equipment, which falls outside of ADDvise’s core business within life science. ADDvise is therefore evaluating options to find a new owner who can further develop Germa and maximize its full potential within the defense segment. Since … Read more